Abstract:Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) and the primary cause of non-traumatic neurologic disability in the western world. Infiltration of myelin-specific effector T cells into the CNS is thought to cause demyelination and loss of axons resulting in deficient signal conduction and clinical onset of the disease. Although previously thought to be initiated by T helper 1 (Th1) cells, it has become evident that Th17 cells are also involved (Cua 2003). In addition, CD8+ T cells, macrophages, and B cells are also found in inflammatory infiltrates in the CNS of affected individuals. During the initial phases of the disease, once the myelin-specific peripherally activated T cells penetrate the CNS, they are re-activated by antigen presenting cells presenting their target antigen within the CNS and act to cause damage to axonal myelin through the activation of macrophages and the release of myelin toxic substances (Aktas, Waiczies et al. 2007). One of the main obstacles to recovery and to the treatment of MS is the relatively low efficiency of spontaneous remyelination of axons by oligodendrocytes. In the majority of cases during the early phases of the disease a large amount of oligodendrocytes and their precursors are preserved within the characteristic demyelination plaques and retain the ability to remyelinate. Despite this resident population of remyelinating cells it has been shown that over time remyelination becomes incomplete and fails, resulting in the irreversible neurological damage associated with the disease (Franklin 2002). The direct cause of MS remains unknown but it seems most likely to be a mixture of both genetic susceptibility and environmental factors. Genetic factors had been long suspected to affect the chances of an individual developing MS. It has been known for some time that there is a familial link to the disease with a sharp increase in disease probability if a family member has the disease (Dyment, Ebers et al. 2004), with a direct correlation between how closely related the affected individual is and the probability of developing the disease. The importance of genetic factors was underscored by the fact that adopted children have no statistically significant increase in there disease susceptibility compared to the general population, even if any of their adoptive family members have the disease. Other genetic factors such as gender and race have also been shown to have an effect (Sospedra and Martin 2005).

Natural history and treatment of multiple sclerosis

Multiple sclerosis: pathogenesis and treatment

Multiple sclerosis. Recent modalities of treatment

Multiple sclerosis: therapeutic update

[Current therapy of multiple sclerosis]

Therapeutic developments in multiple sclerosis

Towards Treating Multiple Sclerosis Progression

Immunomodulatory Therapies of Multiple Sclerosis

Recent advances in understanding the pathogenesis and biological treatment of multiple sclerosis

Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management

Natural History of Benign Multiple Sclerosis: Clinical and HLA Correlates in a Western Australian Cohort

The peculiar difficulties of therapeutic trials for multiple sclerosis

Progress in the Application of Drugs for the Treatment of Multiple Sclerosis

[New therapeutic possibilities for disseminated sclerosis?]

The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease

Investigational drug therapies of treatment of multiple sclerosis

An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis

[Treatments for multiple sclerosis: update]

Cellular Based Therapies for the Treatment of Multiple Sclerosis

Natural compounds as potential therapeutic candidates for multiple sclerosis: Emerging preclinical evidence

Multiple sclerosis: clinical aspects